BEEDAN (Dasatinib Tablets)

Therapeutic class: kinase inhibitor

Indication: Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. , Chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. , Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. , Indicated for the treatment of pediatric patients 1 year of age and older with o Ph+ CML in chronic phase. o newly diagnosed Ph+ ALL in combination with chemotherapy.